Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis

Journal of Clinical Microbiology

Volumn 50, Issue 7, 2012, Pages 2330-2336

  Chai, Louis Y A ^a,b   Kullberg, Bart Jan ^a   Johnson, Elizabeth M ^c   Teerenstra, Steven ^a   Khin, Lay Wai ^b   Vonk, Alieke G ^d   Maertens, Johan ^e   Lortholary, Olivier ^f,g,h   Donnelly, Peter J ^a   Schlamm, Haran T ⁱ   Troke, Peter F ^j   Netea, Mihai G ^a   Herbrecht, Raoul ^k  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f INSTITUT PASTEUR   (France)

^g CNRS   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ Pf Izer Global Research and Development   (United States)

^j Hôpital Necker Enfants Malades ^*  (United Kingdom)

^k UNIVERSITY HOSPITAL OF STRASBOURG   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTINEOPLASTIC AGENT; GALACTOMANNAN; VORICONAZOLE;

ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INVASIVE ASPERGILLOSIS; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; DRUG MONITORING; FEMALE; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MANNANS; PROGNOSIS; ROC CURVE; SERUM; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862738572     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.06513-11     Document Type: Article

References (24)

1. Boutboul F, et al. 2002. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin. Infect. Dis. 34:939-943.
2. De Pauw B, et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
3. Gilbert R, Logan S, Moyer VA, Elliott EJ. 2001. Assessing diagnostic and screening tests: part 1. Concepts. West. J. Med. 174:405-409.
4. Hachem RY, et al. 2009. Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J. Clin. Microbiol. 47:129-133.
5. Herbrecht R, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
6. Koo S, Bryar JM, Baden LR, Marty FM. 2010. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J. Clin. Microbiol. 48:1255-1260.
7. Leeflang MM, et al. 2008. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst. Rev. 2008:CD007394. doi:10.1002/14651858.CD007394.
8. Maertens J, et al. 2009. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 115:355-362.
9. Maertens J, et al. 2005. Galactomannan and computed tomographybased preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin. Infect. Dis. 41:1242-1250.
10. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. 2001. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97:1604-1610.
11. Maertens JA, et al. 2007. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin. Infect. Dis. 44:1329-1336.
12. Marr KA. 2008. Aspergillus galactomannan index: a surrogate end point to assess outcome of therapy? Clin. Infect. Dis. 46:1423-1425.
13. Marr KA, et al. 2004. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J. Infect. Dis. 190:641-649.
14. Mennink-Kersten MA, Donnelly JP, Verweij PE. 2004. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect. Dis. 4:349-357.
15. Miceli MH, et al. 2008. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin. Infect. Dis. 46:1412-1422.
16. Neofytos D, et al. 2009. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis. 48:265-273.
17. Nouer SA, et al. 2011. Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin. Infect. Dis. 53:671-676.
18. Penack O, Rempf P, Graf B, Blau IW, Thiel E. 2008. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann. Oncol. 19:984-989.
19. Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53.
20. Pfeiffer CD, Fine JP, Safdar N. 2006. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin. Infect. Dis. 42:1417-1427.
21. Singh N, Paterson DL. 2005. Aspergillus infections in transplant recipients. Clin. Microbiol. Rev. 18:44-69.
22. Steinbach WJ, et al. 2007. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr. Infect. Dis. J. 26:558-564.
23. Wheat LJ, Walsh TJ. 2008. Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur. J. Clin. Microbiol. Infect. Dis. 27:245-251.
24. Woods G, et al. 2007. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 110:830-834.